The Indian Patent Office ordered Bayer to grant Natco Pharma a compulsory license to produce and market a generic version of cancer medicine Nexavar, marking the first such issuance under the country's patent law. Bayer is disappointed and exploring options to defend its intellectual property, the company said.

Related Summaries